Medrx - Japan Biotech Microcap in Potential Big Licensing Deal
Although the Japanese drug industry suffers from a lack of scale, where it is good is in applying manufacturing techniques to develop not just...
614 Views
Chugai Pharma (4519) - ALEX Trials for Alecensa a Success
Chugai Pharmaceutical (4519 JP) completed the clean sweep on Phase III trials for Alecensa. The latest data, from the ALEX trial, showed its...
223 Views
Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs
Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...
405 Views
Chugai Pharmaceutical: Update Ahead of Summer Data Releases
The excitement at Chugai Pharmaceutical (4519 JP) is palpable for all to see, and you quickly get the impression at any meeting that the company is...
263 Views
Chugai Pharmaceutical-Exceptionally Productive In-House R&D Driving Strong Growth
We publish an in-depth analysis of Chugai Pharmaceutical arriving at a DCF derived fair value of ¥ 4,200. Chugai’s strategic alliance with its...
293 Views